Paysign reported a strong third quarter with a 17% increase in revenue year-over-year and a 29% improvement in net income. The company's growth was evident across all business segments, driven by higher donor rates in the plasma business and substantial revenue growth in the patient affordability segment.
Revenue increased by 17% year-over-year.
Net income improved by 29% year-over-year.
Growth was evident across all business segments.
The company maintains a strong pipeline in every area.
Paysign expects operating improvements in the fourth quarter with year-over-year revenue growth slightly better than this quarter’s revenue growth of 17% and operating expenses equivalent to our second quarter 2023 operating expenses of $6.3 million which reflect seasonal costs relative to the third quarter